Group 1: Earnings Performance - LifeStance Health Group (LFST) reported break-even quarterly earnings per share, surpassing the Zacks Consensus Estimate of a loss of $0.04, and improved from a loss of $0.06 per share a year ago, representing an earnings surprise of 100% [1] - The company posted revenues of $332.97 million for the quarter ended March 2025, slightly missing the Zacks Consensus Estimate by 0.08%, compared to year-ago revenues of $300.44 million [2] - Over the last four quarters, LifeStance Health has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Group 2: Stock Performance and Outlook - LifeStance Health shares have declined approximately 11.1% since the beginning of the year, while the S&P 500 has decreased by 4.7% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is -$0.03 on revenues of $351.71 million, and -$0.10 on revenues of $1.42 billion for the current fiscal year [7] Group 3: Industry Context - The Medical - Outpatient and Home Healthcare industry, to which LifeStance Health belongs, is currently ranked in the top 22% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that tracking these revisions can be beneficial for investors [5] - The favorable estimate revisions trend for LifeStance Health has resulted in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6]

Financial Performance - Q1 2025 revenue reached $333.0 million, an 11% year-over-year increase[10] - Q1 2025 Center Margin was $109.8 million, representing 33.0% of revenue[10] - Q1 2025 Adjusted EBITDA was $34.6 million, or 10.4% of revenue[10] - The company ended Q1 2025 with a cash position of $134.3 million[10] Operational Metrics - Total clinicians reached 7,535, a 10% year-over-year increase, with 152 net clinician additions in Q1[10] - Q1 2025 visit volumes totaled 2.1 million, a 10% year-over-year increase[10] - The company operates over 550 centers in 33 states[8] Future Outlook - The company reaffirmed its FY 2025 revenue guidance of $1.40 billion to $1.44 billion[20] - The company reaffirmed its FY 2025 Adjusted EBITDA guidance of $130 million to $150 million[20] - The company anticipates opening 25 to 30 de novo centers in 2025[23]

Core Insights - LifeStance Health Group, Inc. reported a solid financial performance for Q1 2025, achieving positive net income for the first time as a public company, driven by increased visit volumes and clinician growth [3][6][7]. Financial Highlights - Total revenue for Q1 2025 was $333.0 million, an increase of 11% compared to $300.4 million in Q1 2024 [4][7]. - Income from operations was $1.6 million, a significant improvement from a loss of $16.8 million in the prior year [4][7]. - Net income reached $0.7 million, compared to a net loss of $21.1 million in Q1 2024, marking a 103% improvement [4][7]. - Adjusted EBITDA increased by 25% to $34.6 million, representing 10.4% of total revenue [4][7]. Operational Metrics - The clinician base grew by 10% to 7,535 clinicians, with a net increase of 152 clinicians in Q1 2025 [6]. - Visit volumes increased by 10% to 2.1 million in the first quarter [6]. - Center Margin rose by 16% to $109.8 million, accounting for 33.0% of total revenue [4][7]. Balance Sheet and Cash Flow - As of March 31, 2025, LifeStance had cash of $134.3 million and net long-term debt of $276.3 million [5]. - The company used $3.1 million in cash flow from operations during the first quarter [5][6]. 2025 Guidance - LifeStance expects full-year revenue to be between $1.40 billion and $1.44 billion, with a Center Margin of $440 million to $464 million, and Adjusted EBITDA of $130 million to $150 million [6][12]. - For Q2 2025, the company anticipates total revenue between $332 million and $352 million [12].

Investor Relations Contact "We delivered a solid quarter to kick off 2025, thanks to the commitment and dedication of our employees, including over 7,500 clinicians," said Dave Bourdon, CEO of LifeStance. "We exceeded our financial expectations with double-digit margins as well as positive net income in the quarter for the first time in our history as a public company. We look forward to continuing to enhance the patient and clinician experience at LifeStance while delivering on our mission of expanding acc ...

Group 1 - LifeStance Health Group (LFST) closed at $6.80, with a 2.4% gain over the past four weeks, and a mean price target of $8.75 suggests a 28.7% upside potential [1] - The average price targets range from a low of $7 to a high of $10, with a standard deviation of $1.07, indicating variability among analysts' estimates [2] - Analysts show strong agreement on LFST's ability to report better earnings than previously predicted, which supports the potential for stock upside [4][11] Group 2 - The Zacks Consensus Estimate for LFST has increased by 2.5% due to one upward revision in earnings estimates over the last 30 days, with no negative revisions [12] - LFST holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for near-term upside [13] - While consensus price targets may not be entirely reliable, the implied direction of price movement appears to be a good guide for potential stock performance [13]

Group 1 - The core thesis for LifeStance Health Group (NASDAQ: LFST) is based on the growing demand in the industry, which the company is positioned to capitalize on [1] - The investment approach emphasizes identifying undervalued companies with long-term growth potential, focusing on quality companies purchased at a discount to their intrinsic value [1] Group 2 - The article does not provide any specific financial data or performance metrics related to LifeStance Health Group or the industry [2][3]

Core Viewpoint - LifeStance Health Group, Inc. is set to release its first quarter 2025 earnings on May 7, 2025, before market opening, highlighting its position as a major player in outpatient mental health care [1]. Group 1: Earnings Release Information - LifeStance will host a live earnings conference call on May 7, 2025, at 8:30 a.m. Eastern Time to discuss the first quarter results [2]. - Participants can join the call by dialing specific domestic and international numbers and using a conference ID [2]. - A real-time audio webcast will be available on the LifeStance Investor Relations website, with related materials posted prior to the call [3]. Group 2: Company Overview - Founded in 2017, LifeStance is one of the largest providers of virtual and in-person outpatient mental health care in the U.S. [4]. - The company employs approximately 7,400 mental health professionals and operates over 550 centers across 33 states [4]. - LifeStance aims to improve access to affordable and personalized mental health care, helping individuals lead healthier lives [4].

Company Overview - LifeStance Health Group (LFST) shares increased by 5.8% to close at $6.91, following a relief rally in global markets due to a 90-day pause on tariff hikes by the United States [1] - The stock had previously experienced a 6% loss over the past four weeks [1] Financial Performance Expectations - LifeStance Health is expected to report a quarterly loss of $0.03 per share, reflecting a year-over-year improvement of 50% [2] - Projected revenues for the upcoming quarter are $333.08 million, which is a 10.9% increase compared to the same quarter last year [2] Earnings Estimate Trends - The consensus EPS estimate for LifeStance Health has been revised down by 11.1% over the last 30 days [3] - A negative trend in earnings estimate revisions typically does not lead to price appreciation, indicating potential caution for future stock performance [3] Industry Context - LifeStance Health operates within the Zacks Medical - Outpatient and Home Healthcare industry [3] - Aveanna Healthcare (AVAH), another company in the same industry, saw a 1.9% increase in its stock price, closing at $4.89, with a notable 25.7% return over the past month [3] - Aveanna's EPS estimate has increased by 40% over the past month, indicating a year-over-year change of 100% [4] - Aveanna currently holds a Zacks Rank of 1 (Strong Buy) [4]

Core Viewpoint - LifeStance Health Group (LFST) has experienced a significant downtrend, with a 13.6% decline over the past four weeks, but it is now in oversold territory, suggesting a potential turnaround due to analysts' positive earnings outlook [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is a key technical indicator used to determine if a stock is oversold, with a reading below 30 indicating oversold conditions [2]. - LFST's current RSI reading is 29.22, suggesting that the heavy selling pressure may be exhausting, indicating a possible price rebound [5]. Group 2: Fundamental Indicators - There is a strong consensus among sell-side analysts regarding LFST, with earnings estimates for the current year increasing by 29.8% over the last 30 days, which typically correlates with price appreciation [6]. - LFST holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a near-term turnaround [7].

Reimagining Mental Health Q4 2024 Earnings Presentation • February 27, 2025 Forward-Looking Statements DISCLAIMERS Cautionary Note Regarding Forward-Looking Statements This presentation and related oral statements, including during any question and answer portion of the presentation, contain forward-looking statements about LifeStance Health Group, Inc. and its subsidiaries ("LifeStance") and the industry in which LifeStance operates, including statements regarding: full-year and first quarter guidance and ...